

ACADEMY OF MEDICAL MARIJUANA DISPENSARIES

Connecticut Pharmacists Association

**Testimony Before the General Law Committee
February 25, 2021**

Regarding

HB 6099 AN ACT CONCERNING ANTI-TRUST ISSUES AND THE PALLIATIVE USE OF MARIJUANA

Sen. Maroney, Rep. D'Agostino, Sen. Fonfara, Rep. Gibson, Sen. Witkos and Rep. Rutigliano and members of the Committee:

Thank you for the opportunity to provide testimony regarding HB 6099. The Academy of Medical Marijuana Dispensaries (AMMD) is an affiliate entity within the Connecticut Pharmacists Association. Together, with pharmacists at the core of the program's success, Connecticut's dispensaries serve the health and wellness of over 50,000 patients.

While the Academy supports the idea of a fair and level medical marijuana playing field in Connecticut, HB 6099 presents an unnecessary intrusion into the business workings of the industry and threatens to impede the natural development of an industry that is already highly regulated and subject to intense oversight. We therefore must express strong opposition to HB 6099.

The medical marijuana business in Connecticut is small, comprising just 18 dispensaries and four producers. Since its inception in 2013, there has been some consolidation among those businesses, as would be expected of any growing industry. This consolidation has been driven by natural business development forces, including the significant investment required to launch and build an organization in a highly-regulated industry and the uncertainty of federal interference. Indeed, the consolidation that has occurred has created a more competitive and innovative landscape, rather than less.

Further, the possibility of adult-use marijuana legalization represents a major potential disruption to the medical program; medical marijuana businesses must be prepared should such a major change to the landscape occur.

Finally, there are already regulatory safeguards in place protecting against abuse of the current schema and changes of ownership are already reviewed by the Department of Consumer Protection and Drug Control.

Clearly, there is no imminent threat of anti-competitive practices. Given the small size of the industry, the significant concomitant costs to dispensary owners, and the fact that current consolidation is driven by intense competition among a significant number of entities, mandatory anti-trust review seems intrusive and premature.

The Academy of Medical Marijuana Dispensaries believes that HB 6099 will negatively impact the current success of Connecticut's medical marijuana program. We appreciate the opportunity to comment.

Nathan Tinker, PhD
Secretary, Academy of Medical Marijuana Dispensaries
CEO, Connecticut Pharmacists Association